New Study Shows That Testosterone Therapy Prevents Breast Cancers

DAYTON, Ohio - Oct. 22, 2013 - PRLog -- Dayton, OH.--When it comes to breast cancer, not all hormone therapies are equal. Research has shown, and the medical profession agrees that estrogen and progestin therapy increase the risk of breast cancer. But the impact of testosterone therapy on breast cancer is currently debated.

However, a clinical study by Dr. Rebecca Glaser (Dayton, Ohio) and Dr. Constantine Dimitrakakis (Athens, GR) recently published in Maturitas’, a well-established international journal, puts the debate to rest.

A full report of the study can be viewed online at Medpagetoday. (http://www.medpagetoday.com/HematologyOncology/BreastCancer/41616)

In essence, the study shows that testosterone, or testosterone with an estrogen blocker prevents breast cancer. In women who received therapy on a regular basis, there was over a 3-fold reduction in the incidence of breast cancer.

“Testosterone is breast protective, but it is also the major building block for estrogen, which stimulates breast tissue and breast cancers,” says Glaser. “Identifying women who make too much estrogen from testosterone, and blocking that from occurring is important.”

Glaser and Dimitrakakis have previously demonstrated that testosterone combined with the estrogen blocker anastrozole, delivered as a small implant placed under the skin, also safely relieves symptoms of hormone deficiency in breast cancer survivors.

The two physicians have conducted numerous clinical tests and reported on the benefits of testosterone therapy in women. And they have now documented a reduced incidence of breast cancer in over 1200 women treated with testosterone, or testosterone with an estrogen blocker. They are currently investigating the ability of this combination implant to treat breast cancer itself.

About:

Rebecca L. Glaser, M.D., FACS is an Assistant Clinical Professor, Wright State University, Boonshoft School of Medicine, Department of Surgery.

Constantine Dimitrakakis, M.D., PhD is a Professor at Athens University School of Medicine, Athens, Greece and collaborates with the National Institute of Health, Bethesda, MD.

The original journal article detailing the study can be viewed online:

http://www.hormonebalance.org/pdf/Glaser%20Dim%2013%20Reduced%20BCA%20incidence%20T%20T+%20A

Chip Tudor is a seasoned freelance copywriter that delivers engaging material for marketing communications, advertising, and public relations. He writes in all forms of media for both profit and non-profit organizations. For more information contact: chip@chiptudor.com